241 related articles for article (PubMed ID: 35331006)
1. Single-Dose Intrathecal Dorsal Root Ganglia Toxicity of Onasemnogene Abeparvovec in Cynomolgus Monkeys.
Tukov FF; Mansfield K; Milton M; Meseck E; Penraat K; Chand D; Hartmann A
Hum Gene Ther; 2022 Jul; 33(13-14):740-756. PubMed ID: 35331006
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG).
Finkel RS; Darras BT; Mendell JR; Day JW; Kuntz NL; Connolly AM; Zaidman CM; Crawford TO; Butterfield RJ; Shieh PB; Tennekoon G; Brandsema JF; Iannaccone ST; Shoffner J; Kavanagh S; Macek TA; Tauscher-Wisniewski S
J Neuromuscul Dis; 2023; 10(3):389-404. PubMed ID: 36911944
[TBL] [Abstract][Full Text] [Related]
3. Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
Day JW; Mendell JR; Mercuri E; Finkel RS; Strauss KA; Kleyn A; Tauscher-Wisniewski S; Tukov FF; Reyna SP; Chand DH
Drug Saf; 2021 Oct; 44(10):1109-1119. PubMed ID: 34383289
[TBL] [Abstract][Full Text] [Related]
4. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR
Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238
[TBL] [Abstract][Full Text] [Related]
5. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.
Mercuri E; Muntoni F; Baranello G; Masson R; Boespflug-Tanguy O; Bruno C; Corti S; Daron A; Deconinck N; Servais L; Straub V; Ouyang H; Chand D; Tauscher-Wisniewski S; Mendonca N; Lavrov A;
Lancet Neurol; 2021 Oct; 20(10):832-841. PubMed ID: 34536405
[TBL] [Abstract][Full Text] [Related]
6. Liver injury in cynomolgus monkeys following intravenous and intrathecal scAAV9 gene therapy delivery.
Hudry E; Aihara F; Meseck E; Mansfield K; McElroy C; Chand D; Tukov FF; Penraat K
Mol Ther; 2023 Oct; 31(10):2999-3014. PubMed ID: 37515322
[TBL] [Abstract][Full Text] [Related]
7. Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy.
Blair HA
CNS Drugs; 2022 Sep; 36(9):995-1005. PubMed ID: 35960489
[TBL] [Abstract][Full Text] [Related]
8. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.
Bischof M; Lorenzi M; Lee J; Druyts E; Balijepalli C; Dabbous O
Curr Med Res Opin; 2021 Oct; 37(10):1719-1730. PubMed ID: 34236007
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological and clinical profile of Onasemnogene Aveparvovec, the first gene therapy for spinal muscular atrophy (SMA)].
Atsumi A; Yoneda T; Tsuchida K; Kagawa Y; Tominaga S; Kawase K; Kikuchi N
Nihon Yakurigaku Zasshi; 2022; 157(1):53-61. PubMed ID: 34980814
[TBL] [Abstract][Full Text] [Related]
10. Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy.
René CA; Parks RJ
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376212
[TBL] [Abstract][Full Text] [Related]
11. Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology.
Hordeaux J; Buza EL; Dyer C; Goode T; Mitchell TW; Richman L; Denton N; Hinderer C; Katz N; Schmid R; Miller R; Choudhury GR; Horiuchi M; Nambiar K; Yan H; Li M; Wilson JM
Hum Gene Ther; 2020 Aug; 31(15-16):808-818. PubMed ID: 32845779
[TBL] [Abstract][Full Text] [Related]
12. Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience.
Friese J; Geitmann S; Holzwarth D; Müller N; Sassen R; Baur U; Adler K; Kirschner J
J Neuromuscul Dis; 2021; 8(2):209-216. PubMed ID: 33427694
[TBL] [Abstract][Full Text] [Related]
13. Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec.
Retson L; Tiwari N; Vaughn J; Bernes S; Adelson PD; Mansfield K; Libertini S; Kuzmiski B; Alecu I; Gabriel R; Mangum R
Mol Ther; 2023 Oct; 31(10):2991-2998. PubMed ID: 37598295
[TBL] [Abstract][Full Text] [Related]
14. Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5 kg or Heavier in a Global Managed Access Program.
Chand DH; Mitchell S; Sun R; LaMarca N; Reyna SP; Sutter T
Pediatr Neurol; 2022 Jul; 132():27-32. PubMed ID: 35605311
[TBL] [Abstract][Full Text] [Related]
15. From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1.
Al-Zaidy SA; Mendell JR
Pediatr Neurol; 2019 Nov; 100():3-11. PubMed ID: 31371124
[TBL] [Abstract][Full Text] [Related]
16. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
Bitetti I; Lanzara V; Margiotta G; Varone A
Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
[TBL] [Abstract][Full Text] [Related]
17. Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec.
Day JW; Finkel RS; Mercuri E; Swoboda KJ; Menier M; van Olden R; Tauscher-Wisniewski S; Mendell JR
Mol Ther Methods Clin Dev; 2021 Jun; 21():76-82. PubMed ID: 33768131
[TBL] [Abstract][Full Text] [Related]
18. Onasemnogene Abeparvovec: First Global Approval.
Hoy SM
Drugs; 2019 Jul; 79(11):1255-1262. PubMed ID: 31270752
[TBL] [Abstract][Full Text] [Related]
19. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.
Chand D; Mohr F; McMillan H; Tukov FF; Montgomery K; Kleyn A; Sun R; Tauscher-Wisniewski S; Kaufmann P; Kullak-Ublick G
J Hepatol; 2021 Mar; 74(3):560-566. PubMed ID: 33186633
[TBL] [Abstract][Full Text] [Related]
20. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
